scholarly journals Clinical and angiographic profile of symptomatic patients undergoing percutaneous transluminal coronary angioplasty and drug-eluting stent implantation

2019 ◽  
Vol 7 (10) ◽  
pp. 3819
Author(s):  
V.S.R. Bhupal ◽  
P. Sampath Kumar
Keyword(s):  
Coronary Angioplasty ◽  
Tertiary Care ◽  
Percutaneous Transluminal Coronary Angioplasty ◽  
Drug Eluting Stent ◽  
Stent Restenosis ◽  
Paclitaxel Group ◽  
Drug Eluting ◽  
Transluminal Coronary Angioplasty ◽  
Percutaneous Transluminal ◽  
In Stent Restenosis

Background: There are limited number of studies in India which have looked at this clinical and angiographic characteristic of the disease. Thus, this study was conducted to assess the clinical and angiographic profile of symptomatic patients who underwent percutaneous transluminal coronary angioplasty (PTCA) and drug-eluting stent (DES) implantation.Methods: This was an observational study conducted at a tertiary-care center in India between November 2014 and November 2015. A total of 106 consecutive patients who received either Cypher/Xience/BioMime stent presented with anginal symptoms were included in the study. Based on the type of stent received, patients were divided into two groups: (A) Limus group; (B) Paclitaxel group. Coronary angiogram was done in all the patients. Angioplasty data were collected from patient records. Angiographic profiles of the two groups were compared and analysed.Results: Among the 106 patients, 54 patients were included in the Limus group and 52 patients were included in the Taxus stent. De novo lesions were found to be significantly higher in the Limus group (40(74%), p = 0.06) whereas the in-stent restenosis was found to be significantly higher in the paclitaxel group (22(42.3%), p = 0.08). At follow-up, the incidence of death was 0% and no patients suffered by myocardial infarction. One (1.8%), two (3.8%) patients from the Limus and Paclitaxel groups had target vessel revascularization, respectively.Conclusions: Development of lesions in new areas rather than in-stent restenosis is the cause for angina in the majority of patients who underwent angioplasty presenting with anginal symptoms.

PTCA in elderly patients: hospital events

1993 ◽  
Vol 2 (2) ◽  
pp. 171-176 ◽  
Author(s):  
MA McGrath ◽  
GI Peet ◽  
JG Franke ◽  
RR Mildenberger ◽  
JE Morch ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Adverse Events ◽  
Coronary Angioplasty ◽  
Tertiary Care ◽  
The Elderly ◽  
Percutaneous Transluminal Coronary Angioplasty ◽  
Artery Disease ◽  
Transluminal Coronary Angioplasty ◽  
Percutaneous Transluminal

BACKGROUND: Medical treatment of the elderly is changing to include the aggressive management of coronary artery disease with percutaneous transluminal coronary angioplasty. OBJECTIVE: The purpose of this study was to review major hospital events of patients aged 70 years or more, who underwent a first percutaneous transluminal coronary angioplasty. METHODS: A retrospective medical record review was done of 246 consecutive patients of 70 years or more, from January 1985 to December 1988, at a tertiary care community hospital. Adverse events and the factors that influenced outcome were identified. RESULTS: Of 246 patients (age range, 70-85 years, mean = 73.6), 19 died, 4 had a cerebral vascular accident, 11 had a transfusion and 11 underwent coronary artery bypass grafting. Sixteen patients had acute vessel closure and 8 died. Twenty-five patients had one event and 21 patients had more than one. DISCUSSION: The event rate after percutaneous transluminal coronary angioplasty in the elderly is high. CONCLUSIONS: Knowledge of the factors that influence adverse events (diagnostic category, success of procedure, degree of coronary artery disease and age) will assist the critical care team to plan and implement appropriate care.

scholarly journals Diagnostic Dilemma of Wide Complex QRS Tachycardia after PCI: A Case Report

2018 ◽  
Vol 03 (01) ◽  
pp. 027-030
Author(s):  
Sudhakar Kanumuri ◽  
Neeharika Jonnalagadda
Keyword(s):  
Percutaneous Transluminal Coronary Angioplasty ◽  
Drug Eluting Stent ◽  
Coronary Angiogram ◽  
Diagnostic Dilemma ◽  
Vessel Disease ◽  
The Third ◽  
Drug Eluting ◽  
Transluminal Coronary Angioplasty ◽  
Percutaneous Transluminal ◽  
Single Vessel Disease

AbstractThe authors report a case of a 64-year-old woman who presented with breathlessness on exertion for 6 months, for which coronary angiogram (CAG) was done, which showed single-vessel disease of the left anterior descending coronary artery (LAD). The patient underwent PTCA + DES (percutaneous transluminal coronary angioplasty + drug-eluting stent) to mid LAD. On the third postprocedural day, she complained of palpitations with chest pain. Electrocardiographic monitor showed wide complex QRS tachycardia and she was hemodynamically stable. Further evaluation showed potassium of 2.8 mEq/L, for which intravenous (IV) KCl (potassium chloride) correction was given, and recheck CAG was done, which showed patent stent. Meanwhile, the patient was evaluated for the cause of hypokalemia, and no definite cause was evident.

Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis

2016 ◽  
Vol 23 (4) ◽  
pp. 642-647 ◽  
Author(s):  
Naotaka Murata ◽  
Mitsuyoshi Takahara ◽  
Yoshimitsu Soga ◽  
Masatsugu Nakano ◽  
Yasutaka Yamauchi ◽  
...  
Keyword(s):  
Percutaneous Transluminal Angioplasty ◽  
Transluminal Angioplasty ◽  
Drug Eluting Stent ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
Percutaneous Transluminal ◽  
In Stent Restenosis

scholarly journals Stents in interventional cardiology

Medicina ◽  
2007 ◽  
Vol 43 (3) ◽  
pp. 183 ◽  
Author(s):  
Virgilijus Grinius ◽  
Ramūnas Navickas ◽  
Ramūnas Unikas
Keyword(s):  
Stent Thrombosis ◽  
Coronary Angioplasty ◽  
Interventional Cardiology ◽  
Percutaneous Transluminal Coronary Angioplasty ◽  
Coronary Stenting ◽  
Drug Eluting Stents ◽  
Restenosis Rate ◽  
Drug Eluting ◽  
Transluminal Coronary Angioplasty ◽  
Percutaneous Transluminal

Since the first percutaneous transluminal coronary angioplasty performed by A. Gruentzig in 1977, percutaneous coronary interventions have become the most important treatment modality for coronary heart disease. Coronary angioplasty carried a significant risk of coronary flow-limiting dissections and restenosis during the first six months following the procedure. Two main studies comparing percutaneous transluminal coronary angioplasty and coronary stenting (STRESS and BENESTENT) performed in 1994 showed a significant reduction in restenosis rate using stents. Thus, until now stents are the most widely used devices for coronary intervention despite two problems: subacute stent thrombosis (1–2%) and still high restenosis rate (5–40%). Subacute stent thrombosis occurs within the first month after stent placement and can be prevented using the double antiplatelet regimen with aspirin and clopidogrel. Some risk of subacute thrombosis remains beyond the first month when drug-eluting stents are used. This requires prolonged antiplatelet therapy. Drugeluting stents are the most significant innovation in interventional cardiology. They can reduce the incidence of restenosis in native stable coronary arteries to 3–5%. However, the long-term studies comparing bare-metal stents and drug-eluting stents did not show any significant differences in the rate of major adverse cardiac events (death, myocardial infarction), especially in patients with diabetes after the treatment of bifurcational lesions. According to proposed recommendations, drug-eluting stents should be used in small vessels, restenotic lesions, and in saphenous vein grafts. Despite some disadvantages, the results of coronary stenting using drugeluting stents continue to improve.

Sign in / Sign up

Export Citation Format

Share Document